Associated Papers
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
40970755 (PubMed )
Supplement: crc-25-0188_supplementary_table_s7_suppst7.xlsx › Supplementary_Table_S7
Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.
Wu Y et al.
Nature Communications, 2024
39543210 (PubMed )
Supplement: 41467_2024_54254_MOESM4_ESM.xlsx › No.5
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
The status of KRAS mutations in primary ovarian clear cell carcinoma: An analysis of 17 Taiwanese patients.
Wang PC et al.
Taiwanese Journal of Obstetrics & Gynecology, 2023
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.
Loree JM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia.
Canaani J et al.
Oncotarget, 2020
Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies.
Prieto-Potin I et al.
Peerj, 2020
33083132 (PubMed )
Supplement: peerj-08-10069-s009.xlsx › Table_S4
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM et al.
Cold Spring Harbor Perspectives in Medicine, 2018
Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ et al.
Oncotarget, 2016
Select a paper to view details